Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 3, 2002, Pages 739-747

  Antonadou, Dosia ^a   Pepelassi, Marizenia ^a   Synodinou, Maria ^a   Puglisi, Maria ^a   Throuvalas, Nicolas ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Amifostine; Cytoprotection; Head and neck cancer; Mucositis; Xerostomia

Indexed keywords

CONTROL SYSTEMS; RADIOTHERAPY; TOXICITY; TUMORS;

MUCOSITIS;

CHEMOTHERAPY;

AMIFOSTINE; CARBOPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TUMOR LOCALIZATION; XEROSTOMIA;

AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; STOMATITIS; XEROSTOMIA;

EID: 0036498533     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02683-9     Document Type: Article

References (39)

1. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma
2. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
3. Characterization of radiation sensitivity of human squamous carcinoma A431 cells
4. The hazard of accelerated tumor clonogen repopulation during radiotherapy
5. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
6. Concurrent chemoradiation in the treatment of head and neck cancer
7. Ethyol® (amifostine) provides multilineage hematoprotection and protection against non-hematologic toxicities induced by radiochemotherapy of head and neck cancer
8. Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy
9. Amifostine: A radioprotector in locally advanced head and neck tumors
10. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma
11. Clinical study of the radioprotective effects of amifostine (TM-08310, WR-2721) on chronic radiation injury
12. Protection of salivary glands by amifostine in patients treated with high dose radioiodine
13. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy
14. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction
15. Phase III randomized trial of amifostine as radioprotector in head and neck cancer
16. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: A randomised phase II study
17. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors
18. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
19. Daily amifostine given concomitantly to chemoradiation in head and neck cancer: A pilot study
20. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group randomized trial
21. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial
22. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
23. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099
24. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results
25. Paclitaxel, 5-fluorouacil, hydroxyurea, and concomitant radiation therapy for poor prognosis head and neck cancer
26. Five-year update of a randomized trial of alternating radiotherapy, and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck
27. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy
28. Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis
29. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
30. Pharmacokinetics of WR-2721
31. Dental lesions observed after roentgentherapy in cancer of the buccal cavity, pharynx and larynx
32. Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer
33. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma
34. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer
35. The effect of overall treatment time of radiation therapy on local control of T1-stage squamous cell carcinoma of the glottis
36. Radiation therapy for T1, 2 glottic carcinoma: Impact of overall treatment time on local control
37. Avoidance of treatment interruption: An unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas?
38. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts: New evidence for accelerated proliferation from Radiation Therapy Oncology Group protocol 8313